An epilepsy commentary discusses hypersensitivity evidence from different study types, including spontaneous adverse-event reporting.
The supplied article comments on a pediatric clinical study and a pharmacovigilance analysis of severe skin reactions. Such reports can identify medicines needing attention, including clorazepate, but they do not share the same denominator or method of attributing causation.
Spontaneous-report databases can include incomplete information, reporting bias, duplicate or confounded cases and no requirement for confirmed causality. They do not count every exposed patient. The commentary should not be cited as a new cohort establishing clorazepate’s absolute skin-reaction incidence. Its useful contribution is interpretive: drug-specific signals warrant careful clinical assessment, while exposure dates, co-medications, diagnosis and alternatives determine an individual reaction assessment. Population percentages from a different study cannot simply be assigned to clorazepate.
Original analysis of the supplied journal article, identified as PMC6610416.